hepatocellular carcinoma
Conditions
Interventions
Non-response to treatment group:None
Response to treatment group:None
Sponsors
The First People's Hospital of Fuyang
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18 to 75 years old, with no gender restrictions. 2. Pathologically or cytologically confirmed as having hepatocellular carcinoma (HCC). 3. Comply with the clinical guidelines for sorafenib treatment indications and plan to start or have already started standard sorafenib treatment. 4. Able to provide blood samples before treatment; if surgical treatment is received, able to provide postoperative tumor tissue samples (paraffin blocks or fresh frozen tissues). 5. Voluntary participation in this study and signing a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with active malignant tumors other than HCC. 2. Those unable to cooperate in completing regular follow-up and clinical data collection. 3. Those known to have severe allergies to sorafenib or its excipients. 4. Those with any other medical conditions that the investigator deems may interfere with the study results or increase patient risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;miR-194-5p expression level;REV3L expression level; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease control rate;Progression free survival;Overall Survival; | — |
Countries
China
Contacts
Public ContactWeiming Yu
The First People's Hospital of Fuyang
Outcome results
None listed